|
"lin yun chu"的相关文件
显示项目 1-10 / 17 (共2页) 1 2 > >> 每页显示[10|25|50]项目
臺大學術典藏 |
2022-04-26T08:21:05Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Xavier Cheng-Hong; Hou, Hsin-An; Tien, Feng-Ming; Liu, Jia-Hau; WEN-CHIEN CHOU; Ko, Bor-Sheng; Chen, Yu-Wen; Lin, Chien-Chin; Cheng, Chieh-Lung; Lo, Min-Yen; Lin, Yun-Chu; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
臺大學術典藏 |
2022-03-04T03:52:50Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Xavier Cheng-Hong; Hou, Hsin-An; TIEN FENG-MING; LIU JIA-HAU; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; Lin, Chien-Chin; Cheng, Chieh-Lung; Lo, Min-Yen; LIN YUN-CHU; Lu, Li-Chun; SHANG-JU WU; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
臺大學術典藏 |
2022-01-12T08:28:38Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Xavier Cheng-Hong; Hou, Hsin-An; TIEN FENG-MING; LIU JIA-HAU; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; Lin, Chien-Chin; Chieh-Lung Cheng; Lo, Min-Yen; LIN YUN-CHU; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
臺大學術典藏 |
2022-01-10T09:11:05Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Cheng-Hong; Hou, Hsin-An; TIEN FENG-MING; LIU JIA-HAU; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; Lin, Chien-Chin; Cheng, Chieh-Lung; Lo, Min-Yen; LIN YUN-CHU; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
臺大學術典藏 |
2021-11-24T07:22:42Z |
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu-Wen; Tsai, Xavier Cheng-Hong; Hou, Hsin-An; TIEN FENG-MING; LIU JIA-HAU; Chou, Wen-Chien; Ko, Bor-Sheng; Chen, Yu-Wen; CHIEN-CHIN LIN; Cheng, Chieh-Lung; Lo, Min-Yen; LIN YUN-CHU; Lu, Li-Chun; Wu, Shang-Ju; Kuo, Sung-Hsin; Hong, Ruey-Long; Huang, Tai-Chung; MING YAO |
臺大學術典藏 |
2021-11-21T23:19:44Z |
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang, Yu Wen; Tsai, Xavier Cheng Hong; HSIN-AN HOU; Tien, Feng Ming; Liu, Jia Hau; WEN-CHIEN CHOU; BOR-SHENG KO; YU-WEN CHEN; CHIEN-CHIN LIN; Cheng, Chieh Lung; Lo, Min Yen; Lin, Yun Chu; Lu, Li Chun; SHANG-JU WU; SUNG-HSIN KUO; Hong, Ruey Long; TAI-CHUNG HUANG; MING YAO |
臺大學術典藏 |
2021-07-21T03:42:30Z |
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
|
Wang Y.-W.; Tsai C.-H.; Lin C.-C.; Tien F.-M.; Chen Y.-W.; Lin H.-Y.; Yao M.; LIN YUN-CHU; Lin C.-T.; Cheng C.-L.; Tang J.-L.; Chou W.-C.; Hou H.-A.; Tien H.-F. |
臺大學術典藏 |
2021-07-21T03:42:30Z |
GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution
|
Hou H.-A.; LIN YUN-CHU; Kuo Y.-Y.; Chou W.-C.; Lin C.-C.; Liu C.-Y.; Chen C.-Y.; Lin L.-I.; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Huang S.-Y.; Ko B.-S.; Hsu S.-C.; Wu S.-J.; Tsay W.; Chen Y.-C.; Tien H.-F. |
臺大學術典藏 |
2021-07-21T03:42:29Z |
ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
|
Wang Y.-H.; Lin C.-C.; Lee S.-H.; Tsai C.-H.; Wu S.-J.; Hou H.-A.; Huang T.-C.; Kuo Y.-Y.; Yao M.; Chang K.; Lin C.-W.; LIN YUN-CHU; Tien F.-M.; Chou W.-C.; Tang J.-L.; Tien H.-F. |
臺大學術典藏 |
2020-12-09T00:46:09Z |
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
|
Wang, Yu-Wen; Tsai, Cheng-Hong; Lin, Chien-Chin; Tien, Feng-Ming; Chen, Yu-Wen; Lin, Hsing-Yu; MING YAO; Lin, Yun-Chu; Lin, Chien-Ting; Chieh-Lung Cheng; Tang, Jih-Luh; Chou, Wen-Chien; Hou, Hsin-An; Tien, Hwei-Fang |
显示项目 1-10 / 17 (共2页) 1 2 > >> 每页显示[10|25|50]项目
|